Literature DB >> 24513543

Insulin-like growth factor binding protein-related protein 1 and cancer.

Shuzhen Zhu1, Fangying Xu2, Jing Zhang3, Wenjing Ruan4, Maode Lai5.   

Abstract

Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) belongs to the IGFBP family whose members have a conserved structural homology. It has a low affinity for IGFs and a high affinity for insulin, suggesting that IGFBP-rP1 may have a biological function distinct from other members of the family. IGFBP-rP1 is ubiquitously expressed in normal human tissues and has diverse biological functions, regulating cell proliferation, apoptosis and senescence; it may also have a key role in vascular biology. Increasing evidence suggests that IGFBP-rP1 acts as a tumor suppressor. It elicits its biological effects by both insulin/IGF-dependent and -independent mechanisms. This paper provides a brief overview of the structure and regulation of IGFBP-rP1 and its various biological functions in cancer, as well as the underlying molecular mechanisms.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; IGF; IGFBP-rP1

Mesh:

Substances:

Year:  2014        PMID: 24513543     DOI: 10.1016/j.cca.2014.01.037

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  Mesenchymal Stromal Cells Mitigate Experimental Colitis via Insulin-like Growth Factor Binding Protein 7-mediated Immunosuppression.

Authors:  Yan Liao; Junxia Lei; Muyun Liu; Wanwen Lin; Dongxi Hong; Ying Tuo; Mei Hua Jiang; Huimin Xia; Maosheng Wang; Weijun Huang; Andy Peng Xiang
Journal:  Mol Ther       Date:  2016-07-09       Impact factor: 11.454

Review 2.  Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications.

Authors:  Joseph L Alge; John M Arthur
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-04       Impact factor: 8.237

Review 3.  Role of insulin-like growth factor-binding proteins in the pathophysiology and tumorigenesis of gastroesophageal cancers.

Authors:  Manoj K Kashyap
Journal:  Tumour Biol       Date:  2015-09-14

Review 4.  Insulin-like growth factor system in cancer: novel targeted therapies.

Authors:  Varsha P Brahmkhatri; Chinmayi Prasanna; Hanudatta S Atreya
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

5.  Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy.

Authors:  Yi Sun; Wei Chen; Robert J Torphy; Sheng Yao; Gefeng Zhu; Ronggui Lin; Roberta Lugano; Emily N Miller; Yuki Fujiwara; Li Bian; Linghua Zheng; Sudarshan Anand; Fan Gao; Weizhou Zhang; Sarah E Ferrara; Andrew E Goodspeed; Anna Dimberg; Xiao-Jing Wang; Barish H Edil; Carlton C Barnett; Richard D Schulick; Lieping Chen; Yuwen Zhu
Journal:  Sci Transl Med       Date:  2021-07-28       Impact factor: 17.956

6.  Discovery of novel biomarkers for atherosclerotic aortic aneurysm through proteomics-based assessment of disease progression.

Authors:  Hiroaki Yagi; Mitsuhiro Nishigori; Yusuke Murakami; Tsukasa Osaki; Sayaka Muto; Yutaka Iba; Kenji Minatoya; Yoshihiko Ikeda; Hatsue Ishibashi-Ueda; Takayuki Morisaki; Hitoshi Ogino; Hiroshi Tanaka; Hiroaki Sasaki; Hitoshi Matsuda; Naoto Minamino
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379

7.  IGFBP‑rP1‑silencing promotes hypoxia‑induced angiogenic potential of choroidal endothelial cells via the RAF/MEK/ERK signaling pathway.

Authors:  Shuting Zhu; Hong Wang; Zhihua Zhang; Mingming Ma; Zhi Zheng; Xun Xu; Tao Sun
Journal:  Mol Med Rep       Date:  2020-10-11       Impact factor: 2.952

8.  SNORD116 and growth hormone therapy impact IGFBP7 in Prader-Willi syndrome.

Authors:  Sanaa Eddiry; Gwenaelle Diene; Catherine Molinas; Juliette Salles; Françoise Conte Auriol; Isabelle Gennero; Eric Bieth; Boris V Skryabin; Timofey S Rozhdestvensky; Lisa C Burnett; Rudolph L Leibel; Maithé Tauber; Jean Pierre Salles
Journal:  Genet Med       Date:  2021-05-26       Impact factor: 8.822

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.